• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Artiva Biotherapeutics Inc.

    8/1/24 4:18:06 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARTV alert in real time by email
    SC 13G 1 tm2420516d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Artiva Biotherapeutics, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

     

    (Title of Class of Securities)

     

    04317A107

     

    (CUSIP Number)

     

    July 22, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

      

     

     

     

     

    CUSIP No. 04317A107 Page 2 of 17

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners III, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,609,569 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,609,569 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,609,569 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.9% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

      

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.
       
    (2)Consists of (i) 227,672 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 22,762 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 1,359,135 shares held by Venrock Healthcare Capital Partners EG, L.P.
       
    (3)This percentage is calculated based upon 23,281,561 shares of Common Stock outstanding as of July 22, 2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the Securities and Exchange Commission (the “SEC”) on July 22, 2024.

     

     

     

     

     

    CUSIP No. 04317A107 Page 3 of 17

     

    1.

    Names of Reporting Persons

     

    VHCP Co-Investment Holdings III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,609,569 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,609,569 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,609,569 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.9% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

       

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.
       
    (2)Consists of (i) 227,672 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 22,762 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 1,359,135 shares held by Venrock Healthcare Capital Partners EG, L.P.
       
    (3)This percentage is calculated based upon 23,281,561 shares of Common Stock outstanding as of July 22, 2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the SEC on July 22, 2024.

     

     

     

     

      

    CUSIP No. 04317A107 Page 4 of 17

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners EG, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,609,569 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,609,569 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,609,569 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.9% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

      

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.
       
    (2)Consists of (i) 227,672 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 22,762 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 1,359,135 shares held by Venrock Healthcare Capital Partners EG, L.P.
       
    (3)This percentage is calculated based upon 23,281,561 shares of Common Stock outstanding as of July 22, 2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the SEC on July 22, 2024.

      

     

     

     

     

    CUSIP No. 04317A107 Page 5 of 17

     

    1.

    Names of Reporting Persons

     

    VHCP Management III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,609,569 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,609,569 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,609,569 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.9% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

      

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.
       
    (2)Consists of (i) 227,672 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 22,762 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 1,359,135 shares held by Venrock Healthcare Capital Partners EG, L.P.
       
    (3)This percentage is calculated based upon 23,281,561 shares of Common Stock outstanding as of July 22, 2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the SEC on July 22, 2024.

     

     

     

     

     

    CUSIP No. 04317A107 Page 6 of 17

     

    1.

    Names of Reporting Persons

     

    VHCP Management EG, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,609,569 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,609,569 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,609,569 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.9% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

      

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.
       
    (2)Consists of (i) 227,672 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 22,762 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 1,359,135 shares held by Venrock Healthcare Capital Partners EG, L.P.
       
    (3)This percentage is calculated based upon 23,281,561 shares of Common Stock outstanding as of July 22, 2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the SEC on July 22, 2024.

     

     

     

     

     

    CUSIP No. 04317A107 Page 7 of 17

     

    1.

    Names of Reporting Persons

     

    Shah, Nimish

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,609,569 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,609,569 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,609,569 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.9% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 227,672 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 22,762 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 1,359,135 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 23,281,561 shares of Common Stock outstanding as of July 22, 2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the SEC on July 22, 2024.

     

     

     

     

     

    CUSIP No. 04317A107 Page 8 of 17

     

    1.

    Names of Reporting Persons

     

    Koh, Bong

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,609,569 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,609,569 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,609,569 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.9% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 227,672 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 22,762 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 1,359,135 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 23,281,561 shares of Common Stock outstanding as of July 22, 2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the SEC on July 22, 2024.

     

     

     

     

     

    CUSIP No. 04317A107 Page 9 of 17

     

    Item 1.
     
      (a)

    Name of Issuer

     

    Artiva Biotherapeutics, Inc.

     
      (b)

    Address of Issuer’s Principal Executive Offices

     

    5505 Morehouse Drive, Suite 100

    San Diego, CA 92121

     
    Item 2.
     
      (a)

    Name of Person Filing

     

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

     

      (b) Address of Principal Business Office or, if none, Residence
             
        New York Office: Palo Alto Office:  
             
        7 Bryant Park 3340 Hillview Avenue  
        23rd Floor Palo Alto, CA 94304  
        New York, NY 10018    

     
      (c)

    Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     
      (d)

    Title of Class of Securities

     

    Common Stock, $0.0001 par value

     
      (e)

    CUSIP Number

     

    04317A107

     
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable

     

     

     

     

     

    CUSIP No. 04317A107 Page 10 of 17

     

    Item 4. Ownership  
      (a) Amount beneficially owned:  

     

      Venrock Healthcare Capital Partners III, L.P.    1,609,569 (1)
      VHCP Co-Investment Holdings III, LLC    1,609,569 (1)
      Venrock Healthcare Capital Partners EG, L.P.    1,609,569 (1)
      VHCP Management III, LLC    1,609,569 (1)
      VHCP Management EG, LLC    1,609,569 (1)
      Nimish Shah    1,609,569 (1)
      Bong Koh    1,609,569 (1)

     

      (b) Percent of class:  

     

      Venrock Healthcare Capital Partners III, L.P.    6.9 % (2)
      VHCP Co-Investment Holdings III, LLC    6.9 % (2)
      Venrock Healthcare Capital Partners EG, L.P.    6.9 % (2)
      VHCP Management III, LLC    6.9 % (2)
      VHCP Management EG, LLC    6.9 % (2)
      Nimish Shah    6.9 % (2)
      Bong Koh    6.9 % (2)

     

      (c) Number of shares as to which the person has:  

     

        (i)     Sole power to vote or to direct the vote:

     

      Venrock Healthcare Capital Partners III, L.P.   0
      VHCP Co-Investment Holdings III, LLC   0
      Venrock Healthcare Capital Partners EG, L.P.   0
      VHCP Management III, LLC   0
      VHCP Management EG, LLC   0
      Nimish Shah   0
      Bong Koh   0

     

        (ii)     Shared power to vote or to direct the vote:

     

      Venrock Healthcare Capital Partners III, L.P.    1,609,569 (1)
      VHCP Co-Investment Holdings III, LLC    1,609,569 (1)
      Venrock Healthcare Capital Partners EG, L.P.    1,609,569 (1)
      VHCP Management III, LLC    1,609,569 (1)
      VHCP Management EG, LLC    1,609,569 (1)
      Nimish Shah    1,609,569 (1)
      Bong Koh    1,609,569 (1)

     

     

     

     

     

    CUSIP No. 04317A107 Page 11 of 17

     

        (iii)   Sole power to dispose or to direct the disposition of:

     

      Venrock Healthcare Capital Partners III, L.P.   0
      VHCP Co-Investment Holdings III, LLC   0
      Venrock Healthcare Capital Partners EG, L.P.   0
      VHCP Management III, LLC   0
      VHCP Management EG, LLC   0
      Nimish Shah   0
      Bong Koh   0

     

        (iv)   Shared power to dispose or to direct the disposition of:

     

      Venrock Healthcare Capital Partners III, L.P.    1,609,569 (1)
      VHCP Co-Investment Holdings III, LLC    1,609,569 (1)
      Venrock Healthcare Capital Partners EG, L.P.    1,609,569 (1)
      VHCP Management III, LLC    1,609,569 (1)
      VHCP Management EG, LLC    1,609,569 (1)
      Nimish Shah    1,609,569 (1)
      Bong Koh    1,609,569 (1)

      

    (1)Consists of (i) 227,672 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 22,762 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 1,359,135 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

        VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.

     

    (2)This percentage is calculated based upon 23,281,561 shares of Common Stock outstanding as of July 22, 2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the SEC on July 22, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ☐

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable

     

    Item 8. Identification and Classification of Members of the Group
       
      Not applicable

     

     

     

    CUSIP No. 04317A107 Page 12 of 17

     

    Item 9. Notice of Dissolution of Group
       
      Not applicable
     
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

     

    CUSIP No. 04317A107 Page 13 of 17

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: August 1, 2024

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
         
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory

     

     

    VHCP Co-Investment Holdings III, LLC  
       
    By: VHCP Management III, LLC  
    Its: Manager  
       
    By: /s/ Sherman G. Souther  
      Name: Sherman G. Souther  
      Its: Authorized Signatory  

     

     

    VHCP Management III, LLC   VHCP Management EG, LLC
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory

     

     

    Nimish Shah  
       
    /s/ Sherman G. Souther  
    Sherman G. Souther, Attorney-in-fact  

     

     

    Bong Koh  
       
    /s/ Sherman G. Souther  
    Sherman G. Souther, Attorney-in-fact  

      

     

     

     

     

    CUSIP No. 04317A107 Page 14 of 17

      

    EXHIBITS
     
    A:  Joint Filing Agreement
     
    B: Power of Attorney for Nimish Shah
     
    C: Power of Attorney for Bong Koh

     

     

     

     

      

    CUSIP No. 04317A107 Page 15 of 17

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Artiva Biotherapeutics, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

     

    In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 1st day of August, 2024.

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
         
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory

      

     

    VHCP Co-Investment Holdings III, LLC  
       
    By: VHCP Management III, LLC  
    Its: Manager  
       
    By: /s/ Sherman G. Souther  
      Name: Sherman G. Souther  
      Its: Authorized Signatory  

     

     

    VHCP Management III, LLC   VHCP Management EG, LLC
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory

     

     

    Nimish Shah  
       
    /s/ Sherman G. Souther  
    Sherman G. Souther, Attorney-in-fact  

     

     

    Bong Koh  
       
    /s/ Sherman G. Souther  
    Sherman G. Souther, Attorney-in-fact  

      

     

     

     

     

    CUSIP No. 04317A107 Page 16 of 17

     

    EXHIBIT B

     

    POWER OF ATTORNEY FOR NIMISH SHAH

     

    KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

     

    (i)prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

     

    (ii)take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

     

    This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

     

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1st day of August, 2024.

     

    /s/ Nimish Shah  

     

     

     

    CUSIP No. 04317A107 Page 17 of 17

     

    EXHIBIT C

     

    POWER OF ATTORNEY FOR BONG KOH

     

    KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

     

    (i)prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

     

    (ii)take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

     

    This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

     

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1st day of August, 2024.

     

    /s/ Bong Koh  

     

     

    Get the next $ARTV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARTV

    DatePrice TargetRatingAnalyst
    12/30/2024$20.00Buy
    H.C. Wainwright
    8/13/2024$21.00Buy
    Jefferies
    8/13/2024$23.00Overweight
    Cantor Fitzgerald
    8/13/2024Buy
    TD Cowen
    8/13/2024$18.00Outperform
    Wedbush
    8/13/2024$23.00Buy
    Needham
    More analyst ratings

    $ARTV
    SEC Filings

    See more
    • SEC Form 10-Q filed by Artiva Biotherapeutics Inc.

      10-Q - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

      5/8/25 8:06:33 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

      5/8/25 8:03:54 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Artiva Biotherapeutics Inc.

      DEFA14A - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

      4/28/25 9:36:26 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. converted options into 1,058,282 shares, acquired $4,709,207 worth of shares (461,687 units at $10.20) and bought $99,999,996 worth of shares (8,333,333 units at $12.00) (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      7/24/24 4:27:11 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner 5am Partners Vi, Llc converted options into 1,058,284 shares, acquired $4,709,207 worth of shares (461,687 units at $10.20) and bought $9,999,996 worth of shares (833,333 units at $12.00) (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      7/24/24 4:15:09 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Venbio Global Strategic Fund Iii, L.P. bought $4,999,992 worth of shares (416,666 units at $12.00), converted options into 1,058,284 shares and acquired 461,687 shares (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      7/22/24 8:26:49 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Artiva Biotherapeutics Inc.

      SC 13G/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

      11/14/24 4:56:18 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Artiva Biotherapeutics Inc.

      SC 13D/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

      9/3/24 4:18:05 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Artiva Biotherapeutics Inc.

      SC 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

      8/1/24 7:00:07 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Artiva Biotherapeutics with a new price target

      H.C. Wainwright initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $20.00

      12/30/24 7:13:58 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies initiated coverage on Artiva Biotherapeutics with a new price target

      Jefferies initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $21.00

      8/13/24 7:24:03 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Artiva Biotherapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Artiva Biotherapeutics with a rating of Overweight and set a new price target of $23.00

      8/13/24 7:23:42 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Banerjee Subhashis was granted 50,000 shares (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      4/25/25 5:07:02 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Banerjee Subhashis

      3 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      4/25/25 5:03:53 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Aslan Fred was granted 200,000 shares, increasing direct ownership by 92% to 416,665 units (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      3/7/25 4:35:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARTV
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ARTV
    Leadership Updates

    Live Leadership Updates

    See more
    • Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

      IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore an allogeneic cell therapy in refractory rheumatoid arthritis and Sjögren's disease in the U.S. Initial safety, translational data, and lead indication selection to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026 Longer-term clinical data from Phase 1/2 trial exploring AlloNK + rituximab in B-NHL in heavily pretreated CAR-T naïve patients to be presented at ASGCT, demonstrating complete response rates and

      5/8/25 8:00:00 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

      Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK® + rituximab for the treatment of B-cell driven diseases in a community setting Additional poster presentation to feature scalability and consistency of AlloNK manufacturing process SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that the Company will have a poster presentation on new longer-term Phase 1/2 data for AlloNK® (also known

      4/28/25 4:35:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

      SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Subhashis Banerjee, M.D., as Chief Medical Officer. Dr. Banerjee is a trained rheumatologist and immunologist who brings over two decades of clinical development experience in autoimmune diseases, most recently as Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb (BMS), and Senior Vice President (SVP), Clinical Development at VYNE Therapeutics, Inc.

      4/8/25 4:05:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

      IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore an allogeneic cell therapy in refractory rheumatoid arthritis and Sjögren's disease in the U.S. Initial safety, translational data, and lead indication selection to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026 Longer-term clinical data from Phase 1/2 trial exploring AlloNK + rituximab in B-NHL in heavily pretreated CAR-T naïve patients to be presented at ASGCT, demonstrating complete response rates and

      5/8/25 8:00:00 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

      SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Subhashis Banerjee, M.D., as Chief Medical Officer. Dr. Banerjee is a trained rheumatologist and immunologist who brings over two decades of clinical development experience in autoimmune diseases, most recently as Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb (BMS), and Senior Vice President (SVP), Clinical Development at VYNE Therapeutics, Inc.

      4/8/25 4:05:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

      SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker brings over two decades of drug development experience in the pharmaceutical industry. He is currently the interim Chief Development Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at Johnson & Johnson (Janssen/Centocor) (J & J) most recently as the Vice President of Immunology R&D. "Dan is a ph

      1/29/25 4:05:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care